ENvue Medical, Inc. reported that on July 14, 2026, directors David Johnson and Nino Pionati voluntarily resigned from the Board of Directors. The company states their resignations were not due to any disagreement regarding its operations, policies or practices.
The remaining directors appointed Zvi Joseph and Lior Buchman to fill the vacancies. Joseph joined the Audit Committee and the Nominating and Corporate Governance Committee. Buchman joined the Audit Committee and the Compensation Committee and became Compensation Committee Chair. Existing director Zeev Rotstein, M.D. was appointed Chair of the Nominating and Corporate Governance Committee and Chairman of the Board. Joseph and Buchman will receive the same fees as other non‑executive directors, and the company notes there are no special arrangements or related‑party transactions requiring disclosure.
ENvue Medical, Inc. received a Nasdaq Staff Determination Letter on July 10, 2026 stating that its common stock has failed to meet the Nasdaq Capital Market minimum bid price requirement. The closing bid price was below $1.00 per share for 30 consecutive business days from May 26, 2026 through July 8, 2026, violating Nasdaq Listing Rule 5550(a)(2).
Ordinarily the company would receive a 180-calendar day grace period, but under Nasdaq Listing Rule 5810(c)(3)(A)(iv) it is not eligible for any compliance period because it effected a 1-for-10 reverse stock split on August 12, 2025. ENvue Medical plans to request a hearing before a Nasdaq Hearings Panel under the Nasdaq Listing Rule 5800 Series, which will stay any suspension or delisting action while the appeal is pending. The company notes there is no assurance the Panel will grant continued listing or that it will regain and maintain compliance with the Minimum Bid Price Requirement and other Nasdaq standards.
ENvue Medical, Inc. disclosed that shareholder Christian Michael Glibert has fully exited his position in the company’s common stock. On June 22, 2026, he sold his remaining 210,000 shares in open market trades at a weighted average price of $0.6880 per share, with prices ranging from $0.6756 to $0.7220. Following these sales, he beneficially owns 0 shares, representing 0.0% of ENvue’s outstanding common stock, and reports no contracts or arrangements related to the company’s securities.
ENvue Medical, Inc. insider Christian Michael Glibert reported an open-market sale of 210,000 shares of Common Stock at an average price of $0.688 per share. The sale was executed in multiple transactions with prices ranging from $0.6756 to $0.722. Following this transaction, the filing shows that Glibert directly holds 0 shares of ENvue Medical common stock.
ENvue Medical, Inc. registers for resale up to 6,000,768 shares of common stock issuable upon conversion of 6,254 shares of Series H Convertible Preferred Stock at a current conversion price of $1.0422 per share. The resale is by the selling stockholder and the company will receive no proceeds from such sales.
The prospectus states the shares were issued under a private placement and Additional Investment Right tied to a Purchase Agreement dated July 18, 2025. As of April 30, 2026, there were 5,246,513 shares outstanding; the conversion at maximum would substantially increase outstanding shares. The filing lists permitted resale methods and notes Nasdaq listing risks, including past bid-price and equity compliance actions.
ENvue Medical, Inc. registers the resale by a selling stockholder of up to 6,000,768 shares of common stock issuable upon conversion of 6,254 shares of Series H Convertible Preferred Stock at a current conversion price of $1.0422. The company will not receive proceeds from resales. As of April 30, 2026, 5,246,513 shares were outstanding; issuance of the full Conversion Shares would represent approximately 53.4% of outstanding shares as of that date. The prospectus notes Nasdaq listing risks, anti-dilution mechanics, cumulative dividend terms on the Series H, and broad resale methods permitted for the selling holder.
ENvue Medical, Inc. reported a significantly weaker quarter for the three months ended March 31, 2026, with revenues of $653,000 compared with $1,025,000 a year earlier, mainly due to the removal of its higher-margin PainShield Ultra product from the market.
The company generated a gross loss of $55,000 versus a gross profit of $369,000 last year, as margins were pressured by inventory write-downs and amortization of intangibles from the ENvue merger. Operating expenses rose to $3.7 million, driven by higher selling, marketing, and general and administrative costs tied to integrating and commercializing ENvue’s enteral feeding systems.
Net loss widened to $3.8 million, while net loss available to common stockholders reached $22.6 million after recognizing large deemed dividends and down-round adjustments on Series H preferred stock. Cash and cash equivalents fell to $2.2 million, with $4.3 million used in operating activities during the quarter, and the company discloses substantial doubt about its ability to continue as a going concern without additional financing.
ENvue Medical, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company stated it needs additional time to prepare and analyze supporting documentation and anticipates filing the Form 10-Q no later than the fifth calendar day following the prescribed due date. The notice was signed by CEO Doron Besser, M.D. on May 15, 2026.